Stefan Heber: Clinical Trials

2 trials sponsored by Stefan Heber, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 12Completed 2

Follow Stefan Heber: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model
Synthetic interstitial fluid (SIF) / SIF neutral pH, Synthetic interstitial fluid (SIF) / SIF acidic pH, Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µM - Pain
Early Phase 1CompletedStefan Heber422025-06-172025-07-29
Peripheral KV7 Activation for Pain Relief
Capsaicin only (7.6 ng), Capsaicin + Flupirtine 0.5 µg, Capsaicin + Flupirtine 1.2 µg - Pain
Early Phase 1CompletedStefan Heber322025-05-082025-06-10

Conditions studied

Pain (2)  ·  Hyperalgesia (1)  ·  Inflammation (1)

Interventions

Capsaicin (1)  ·  Lipopolysaccharides (1)  ·  azeliragon (1)  ·  ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (1)  ·  flupirtine (1)

Countries

Austria (2)

Results publications

PMID 10191237, PMID 18299127, PMID 20562702, PMID 21270403, PMID 28062311, PMID 30782041, PMID 32107360, PMID 33548580, PMID 33863932, PMID 34293819, PMID 34935141, PMID 42830319, PMID 5781321